Company Overview
Teva Pharmaceutical Industries Limited functions as a developer, manufacturer, marketer, and distributor of generic and other medicines, along with biopharmaceutical products across the United States, Europe, Israel, and international markets. The entity operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, a classification that defines its focus on producing essential medications in various dosage forms such as tablets, capsules, and injectables. The company demonstrates significant scale with a total market capitalization of $34.29B and an annual revenue generated of $17.26B, supported by an employee base of 31173 individuals. These valuation and revenue figures indicate that Teva maintains a substantial position in the pharmaceutical landscape, reflecting its extensive operational footprint and the aggregate economic value assigned by the market to its intellectual property and manufacturing capabilities.
Financial Health
The company reported a trailing twelve-month revenue of $17.26B with a corresponding net income of $1.41B and EBITDA of $4.95B, illustrating a financial structure where the gap between total revenue and net income highlights substantial operating costs, including research, development, and administrative expenses that reduce the bottom line. While the net income represents approximately 8.2% of revenue, the EBITDA figure suggests that earnings before interest, taxes, depreciation, and amortization remain significantly higher at $4.95B, providing a clearer view of core operational profitability before capital structure effects. Free cash flow stands at $2.03B, which indicates a robust capacity to generate liquidity after capital expenditures, thereby offering the company substantial financial flexibility to fund operations, reduce debt, or pursue strategic initiatives. The gross margin is recorded at 51.8%, while the operating margin sits at 27.3% and the profit margin at 8.2%, revealing that for every dollar of sales, the company retains over half as gross profit but faces significant operational overhead that reduces the final profit margin. Balance sheet analysis shows total cash reserves of $3.56B against total debt of $17.23B, resulting in a debt-to-equity ratio of 217.72, which characterizes a highly leveraged balance sheet where interest obligations are substantial relative to equity. Liquidity is assessed via a current ratio of 1.04, indicating that current assets are only slightly higher than current liabilities, suggesting a tight liquidity position where short-term assets barely cover short-term obligations. Return on equity is calculated at 20.8% while return on assets is 6.2%, metrics that reveal management's effectiveness in generating returns for shareholders relative to their equity investment, while the lower ROA reflects the impact of the company's high debt load on overall asset efficiency.
Valuation Assessment
The trailing twelve-month P/E ratio is 24.33, whereas the forward P/E ratio is 9.49, a significant disparity that implies the market expects earnings growth in the future that would drastically lower the multiple, suggesting anticipated improvements in profitability or a correction in current pricing relative to future earnings potential. The price-to-book ratio stands at 4.28, indicating that the market values the company at more than four times its book value, which suggests a premium placed on the company's intangible assets, brand value, and future growth prospects rather than just its tangible net worth. Alternative valuation metrics include a price-to-sales ratio of 1.99 and an EV/EBITDA of 9.59, figures that provide context on valuation relative to sales revenue and enterprise earnings, suggesting the company trades at a moderate multiple of its enterprise earnings despite the high market cap. Price action context is provided by a 52-week high of $37.35 and a 52-week low of $12.47, establishing a wide trading range where the current market price fluctuates significantly relative to this historical volatility band. The stock exhibits a beta of 0.72, meaning its price volatility is lower than the broader market, as a beta below 1.0 indicates that the stock tends to move less aggressively than the overall market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at 11.4%, while earnings growth year-over-year is listed as N/A in the available data, preventing a direct numerical comparison but highlighting the importance of monitoring revenue expansion in the absence of reported earnings growth figures. Since the dividend yield is N/A and the payout ratio is 0.0%, the company does not currently distribute cash to shareholders, indicating a strategy of retaining all earnings to reinvest into growth initiatives, research, or debt management rather than paying dividends. This reinvestment approach is consistent with a capital-intensive business model in the pharmaceutical sector where cash reserves are prioritized for operational expansion and maintaining competitive market share. The overall growth and income profile is defined by strong revenue expansion at 11.4% YoY combined with a lack of dividend distribution, positioning the stock primarily as a growth-oriented investment within the healthcare sector rather than an income-generating vehicle.